Arno Therapeutics Announces Dosing of First Patient in a Phase I/IIa Study of AR-42, a Broad Spectrum Histone and Non-Histone Deacetylation Inhibitor (pan-DAC)

PARSIPPANY, N.J.--(BUSINESS WIRE)--Arno Therapeutics, Inc. (ARNI.PK), a clinical-stage biopharmaceutical company focused on developing oncology therapeutics, today announced the dosing of the first patient in an investigator sponsored Phase I/IIa clinical study of AR-42 (formerly OSU-HDAC42) at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) in adult patients with relapsed or refractory multiple myeloma (MM), chronic lymphocytic leukemia (CLL) or lymphoma.